Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

Published:2014-02-07 Issue:7 Volume:28 Page:1552-1555
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Panagiota V,Thol F,Markus B,Fehse B,Alchalby H,Badbaran A,Lehmann U,Koenecke C,Shahswar R,Chaturvedi A,Stadler M,Eder M,Göhring G,Koenigsmann M,Kloos A,Trummer A,Schroeder T,Kobbe G,Thiede C,Platzbecker U,Schlegelberger B,Kreipe H-H,Ganser A,Kröger N,Heuser M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201466.pdf

Reference16 articles.

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.

2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.

3. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010; 24: 665–683.

4. Chao MP, Majeti R, Weissman IL . Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 2011; 12: 58–67.

5. 1. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013;

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelofibrosis and allogeneic transplantation: critical points and challenges;Frontiers in Oncology;2024-06-20

2. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT;Bone Marrow Transplantation;2023-09-07

3. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT;2023-06-29

4. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation;Blood;2023-03-20

5. High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis;HemaSphere;2022-09-30